Upfront Immunotherapy for Metastatic Kidney Cancer
0 Pogledi
• 06/26/23
0
0
Ugraditi
administrator
Pretplatnici
Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari